Perfuse Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2018-01-01
- Employees
- 11
- Market Cap
- -
Clinical Trials
2
Active:2
Completed:0
Trial Phases
2 Phases
Phase 1:1
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (50.0%)Phase 2
1 (50.0%)A Study of PER-001 in Participants With Diabetic Retinopathy
Phase 2
Active, not recruiting
- Conditions
- Diabetic Retinopathy
- Interventions
- Drug: PER-001 Intravitreal Implant - Low DoseDrug: PER-001 Intravitreal Implant - High DoseDrug: PER-001 Intravitreal Implant - Sham
- First Posted Date
- 2023-08-22
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Perfuse Therapeutics, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT06003751
- Locations
- 🇺🇸
Perfuse Therapeutics, Inc, San Francisco, California, United States
A Study of PER-001 in Participants With Open-Angle Glaucoma
Phase 1
Active, not recruiting
- Conditions
- Open-angle Glaucoma
- Interventions
- Drug: PER-001 Intravitreal Implant - High DoseDrug: PER-001 Intravitreal Implant - Low DoseDrug: PER-001 Intravitreal Implant - Sham
- First Posted Date
- 2023-04-20
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Perfuse Therapeutics, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT05822245
- Locations
- 🇺🇸
Perfuse Therapeutics, Inc., San Francisco, California, United States
News
No news found